DekaBank Deutsche Girozentrale Purchases 33,338 Shares of United Therapeutics Co. (NASDAQ:UTHR)

DekaBank Deutsche Girozentrale increased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 54.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 94,643 shares of the biotechnology company's stock after purchasing an additional 33,338 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.20% of United Therapeutics worth $20,617,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in UTHR. Neo Ivy Capital Management purchased a new position in United Therapeutics in the 2nd quarter worth $48,000. Atlas Capital Advisors LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at about $51,000. Northwestern Mutual Wealth Management Co. increased its position in shares of United Therapeutics by 49.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 65 shares during the period. Zions Bancorporation N.A. purchased a new position in shares of United Therapeutics in the first quarter valued at about $66,000. Finally, Quantbot Technologies LP purchased a new position in shares of United Therapeutics in the second quarter valued at about $87,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In other news, Director Nilda Mesa sold 325 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total transaction of $77,285.00. Following the sale, the director now owns 5,373 shares in the company, valued at $1,277,699.40. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the sale, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Nilda Mesa sold 325 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total transaction of $77,285.00. Following the sale, the director now owns 5,373 shares in the company, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 106,130 shares of company stock worth $24,825,408. 12.50% of the stock is currently owned by company insiders.

United Therapeutics Stock Up 1.5 %

UTHR traded up $3.40 during midday trading on Monday, reaching $236.96. The company's stock had a trading volume of 464,212 shares, compared to its average volume of 430,498. The firm has a market capitalization of $11.15 billion, a price-to-earnings ratio of 11.77 and a beta of 0.52. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a 1 year low of $204.44 and a 1 year high of $261.54. The stock's 50-day moving average is $227.31 and its 200-day moving average is $227.88.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts' consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million for the quarter, compared to analysts' expectations of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business's revenue was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.67 earnings per share. As a group, research analysts expect that United Therapeutics Co. will post 23.46 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs restated an "outperform" rating on shares of United Therapeutics in a research report on Monday, February 5th. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research report on Thursday, March 7th. The Goldman Sachs Group upgraded shares of United Therapeutics from a "sell" rating to a "neutral" rating and boosted their price target for the company from $213.00 to $215.00 in a research report on Monday, February 12th. Finally, Wedbush reiterated an "outperform" rating and set a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $294.40.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.